Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Quanz, Maria; Hagemann, Urs B; Zitzmann-Kolbe, Sabine; Stelte-Ludwig, Beatrix; Golfier, Sven; Elbi, Cem; Mumberg, Dominik; Ziegelbauer, Karl; Schatz, Christoph A

Quanz, Maria; Hagemann, Urs B; Zitzmann-Kolbe, Sabine; Stelte-Ludwig, Beatrix; Golfier, Sven; Elbi, Cem; Mumberg, Dominik; Ziegelbauer, Karl; Schatz, Christoph A.

Quanz M; Bayer AG Preclinical Research, Pharmaceuticals, Berlin 13353, Germany.
Hagemann UB; Bayer AG Preclinical Research, Pharmaceuticals, Berlin 13353, Germany.
Zitzmann-Kolbe S; Bayer AG Preclinical Research, Pharmaceuticals, Berlin 13353, Germany.
Stelte-Ludwig B; Bayer AG Preclinical Research, Pharmaceuticals, Wuppertal 42096, Germany.
Golfier S; Bayer AG Preclinical Research, Pharmaceuticals, Berlin 13353, Germany.
Elbi C; Bayer US LLS, Whippany, NJ 07981, USA.
Mumberg D; Bayer AG Preclinical Research, Pharmaceuticals, Berlin 13353, Germany.
Ziegelbauer K; Bayer AG Preclinical Research, Pharmaceuticals, Berlin 13353, Germany.
Schatz CA; Bayer AG Preclinical Research, Pharmaceuticals, Berlin 13353, Germany.